Viatris Inc. (VTRS) Bundle
Understanding Viatris Inc. (VTRS) Revenue Streams
Understanding Viatris Inc.’s Revenue Streams
For the nine months ended September 30, 2024, the company reported total revenues of $11.21 billion, compared to $11.59 billion for the comparable prior year period, representing a decrease of $378.4 million, or 3%. Total revenues include both net sales and other revenues from third parties.
Net sales for the nine months ended September 30, 2024, were $11.18 billion, compared to $11.56 billion for the comparable prior year period, representing a decrease of $385.1 million, or 3%. Other revenues for the nine months ended September 30, 2024, were $33.8 million, compared to $27.1 million for the comparable prior year period.
Net sales decreased by approximately $445.4 million or 4% due to the inclusion of net sales in the prior year period related to divestitures that have closed during 2023 and 2024. The decrease in net sales was also partially driven by the unfavorable impact of foreign currency translation of approximately $190.9 million, or 2%.
On a constant currency basis, net sales from the remaining business increased by approximately $251.2 million, or 2%, for the nine months ended September 30, 2024, compared to the prior year period. This increase was driven by new product sales of approximately $497.2 million, primarily in developed markets.
Year-over-Year Revenue Growth Rate
Year-over-year, total revenues showed a decline of 3%. This trend can be seen in the following table:
| Period | Total Revenues (in billions) | Year-over-Year Change (%) |
|---|---|---|
| 2024 (9 months) | $11.21 | -3% |
| 2023 (9 months) | $11.59 | N/A |
Contribution of Different Business Segments to Overall Revenue
Net sales are derived from the following four reporting segments:
- Developed Markets
- Greater China
- JANZ
- Emerging Markets
The contribution of each segment for the nine months ended September 30, 2024, is outlined below:
| Segment | Net Sales (in millions) | Percentage Contribution (%) |
|---|---|---|
| Developed Markets | $6,783.3 | 60.7% |
| Greater China | $1,644.7 | 14.7% |
| JANZ | $1,011.7 | 9.0% |
| Emerging Markets | $1,737.7 | 15.5% |
| Total | $11,177.4 | 100% |
Analysis of Significant Changes in Revenue Streams
Significant changes in revenue streams can be attributed to several factors:
- Divestitures leading to reduced net sales.
- Impact of foreign currency translation affecting revenue from international markets.
- New product sales contributing positively to revenue growth.
For the three months ended September 30, 2024, the breakdown of net sales by product category is as follows:
| Product Category | Net Sales (in millions) |
|---|---|
| Brands | $2,362.2 |
| Generics | $1,375.8 |
| Total | $3,738.0 |
A Deep Dive into Viatris Inc. (VTRS) Profitability
Profitability Metrics
Analyzing the profitability of the company provides crucial insights into its financial health. The following sections detail the gross profit, operating profit, and net profit margins, along with trends over time and comparisons with industry averages.
Gross Profit, Operating Profit, and Net Profit Margins
For the nine months ended September 30, 2024, the company reported:
- Gross Profit: $4.41 billion
- Gross Margin: 39%
- Operating Profit: $1.64 billion
- Operating Margin: 14.6%
- Net Profit: -$117.7 million
- Net Margin: -1.05%
In comparison, for the same period in 2023:
- Gross Profit: $4.84 billion
- Gross Margin: 42%
- Operating Profit: $1.01 billion
- Operating Margin: 8.7%
- Net Profit: $820.3 million
- Net Margin: 7.1%
The following table summarizes the profitability metrics:
| Metric | 2024 (9M) | 2023 (9M) |
|---|---|---|
| Gross Profit | $4.41 billion | $4.84 billion |
| Gross Margin | 39% | 42% |
| Operating Profit | $1.64 billion | $1.01 billion |
| Operating Margin | 14.6% | 8.7% |
| Net Profit | - $117.7 million | $820.3 million |
| Net Margin | -1.05% | 7.1% |
Trends in Profitability Over Time
Over the past year, profitability has shown significant volatility. The gross margin has decreased from 42% in 2023 to 39% in 2024, primarily due to increased costs and divestitures. Operating profit has increased from $1.01 billion to $1.64 billion, reflecting improved operational efficiency despite the drop in gross profit. The net profit margin has declined from 7.1% to a negative 1.05% due to substantial goodwill impairment charges.
Comparison of Profitability Ratios with Industry Averages
The company’s profitability ratios are compared to the industry averages as follows:
| Metric | Company | Industry Average |
|---|---|---|
| Gross Margin | 39% | 50% |
| Operating Margin | 14.6% | 20% |
| Net Margin | -1.05% | 5% |
Analysis of Operational Efficiency
Operational efficiency can be assessed through cost management and gross margin trends. The adjusted gross margin for the nine months ended September 30, 2024, was approximately 58%, down from 60% in the prior year. This decline is attributed to the cost of sales, which increased from $6.75 billion to $6.80 billion year-over-year. The company’s SG&A expenses rose by $334.6 million to $3.38 billion, influenced by a goodwill impairment charge and higher acquisition-related costs.
Overall, the company's profitability metrics indicate a challenging environment with pressures from cost increases and divestitures impacting gross and net margins.
Debt vs. Equity: How Viatris Inc. (VTRS) Finances Its Growth
Debt vs. Equity: How Viatris Inc. Finances Its Growth
The financial structure of Viatris Inc. is characterized by a balance between debt and equity financing. As of September 30, 2024, the company reported a total long-term debt of $15.27 billion and short-term debt of $1.11 billion.
Overview of the Company's Debt Levels
Viatris Inc. holds significant long-term liabilities, with the following breakdown:
| Debt Type | Amount (in millions) |
|---|---|
| Long-Term Debt | $15,265.0 |
| Short-Term Debt | $1,114.0 |
| Total Debt | $16,379.0 |
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for Viatris Inc. stands at 0.77, which is below the industry average of 1.0. This indicates a conservative approach to leveraging, suggesting that the company is less reliant on debt compared to its peers in the pharmaceutical industry.
Recent Debt Issuances and Refinancing Activity
In September 2024, Viatris entered into a $3.5 billion amended and restated revolving credit agreement, extending its maturity to September 2029. This refinancing activity demonstrates the company's proactive management of debt obligations.
The aggregate fair value of the company's outstanding notes was approximately $13.40 billion as of September 30, 2024. Notable debt instruments include:
| Debt Instrument | Principal Amount (in millions) | Maturity Date |
|---|---|---|
| 3.125% Euro Senior Notes | $750.0 | 2028 |
| 1.908% Euro Senior Notes | $1,250.0 | 2032 |
| Yen Term Loan | $278.5 | — |
How the Company Balances Between Debt Financing and Equity Funding
As of September 30, 2024, total equity for Viatris Inc. was reported at $19.79 billion, reflecting a decrease from $20.47 billion at the end of 2023. The company has managed its capital structure to ensure liquidity while maintaining a reasonable debt level. This balance allows Viatris to fund operations and potential growth initiatives effectively.
Overall, Viatris Inc. demonstrates a strategic approach to managing its debt and equity, ensuring financial health and stability in an evolving market environment.
Assessing Viatris Inc. (VTRS) Liquidity
Assessing Viatris Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
| Current Assets (in millions) | Current Liabilities (in millions) | Current Ratio |
|---|---|---|
| $11,307.7 | $7,512.4 | 1.51 |
Quick Ratio: The quick ratio, which excludes inventories, is calculated as follows:
| Quick Assets (in millions) | Current Liabilities (in millions) | Quick Ratio |
|---|---|---|
| $7,223.1 | $7,512.4 | 0.96 |
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, is as follows:
| Date | Current Assets (in millions) | Current Liabilities (in millions) | Working Capital (in millions) |
|---|---|---|---|
| September 30, 2024 | $11,307.7 | $7,512.4 | $3,795.3 |
| December 31, 2023 | $12,976.1 | $7,777.4 | $5,198.7 |
Cash Flow Statements Overview
Cash flows from operating, investing, and financing activities for the nine months ended September 30, 2024, are as follows:
| Cash Flow Type | Cash Flow (in millions) |
|---|---|
| Operating Activities | $1,820.2 |
| Investing Activities | $1,969.4 |
| Financing Activities | ($2,910.2) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash and cash equivalents totaled $1.88 billion. The company has access to a $3.5 billion revolving credit facility with no borrowings outstanding as of the reporting date. Additionally, the company maintains a $400 million receivables facility, which is also unutilized. This indicates a solid liquidity position, albeit with a decline in cash flow from operating activities compared to the previous year.
Liquidity metrics reveal a strong current ratio of 1.51 and a quick ratio of 0.96, suggesting adequate short-term financial health despite some operational challenges.
Is Viatris Inc. (VTRS) Overvalued or Undervalued?
Valuation Analysis
Price-to-Earnings (P/E) Ratio
The current P/E ratio stands at 8.6. This is calculated based on a trailing twelve months (TTM) earnings per share (EPS) of $0.92.
Price-to-Book (P/B) Ratio
The P/B ratio is currently 0.65, with a book value per share of $12.3.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is 5.8, calculated using an enterprise value of $28.49 billion and EBITDA of $4.92 billion.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between a low of $9.67 and a high of $13.65. As of September 30, 2024, the stock price is $10.69.
Dividend Yield and Payout Ratios
The current dividend yield is 4.5%, based on an annual dividend of $0.48 per share. The payout ratio is approximately 52% of the earnings.
Analyst Consensus
The consensus among analysts is currently a Hold rating, with a median price target of $11.50.
| Valuation Metric | Value |
|---|---|
| P/E Ratio | 8.6 |
| P/B Ratio | 0.65 |
| EV/EBITDA Ratio | 5.8 |
| 12-Month Low Price | $9.67 |
| 12-Month High Price | $13.65 |
| Current Stock Price | $10.69 |
| Dividend Yield | 4.5% |
| Annual Dividend | $0.48 |
| Payout Ratio | 52% |
| Analyst Consensus | Hold |
| Median Price Target | $11.50 |
Key Risks Facing Viatris Inc. (VTRS)
Risk Factors
Key Risks Facing Viatris Inc.:
- Industry Competition: The pharmaceutical sector is highly competitive, with numerous companies vying for market share. For the nine months ended September 30, 2024, net sales decreased by approximately $445.4 million or 4% due to increased competition and divestitures. The top ten products represented approximately 33% of net sales.
- Regulatory Changes: Regulatory environments are continually evolving. The company has faced challenges due to compliance requirements, impacting operational flexibility and costs. For instance, the goodwill impairment charge of $321 million was primarily influenced by regulatory and market conditions.
- Market Conditions: Economic fluctuations and changes in foreign exchange rates can adversely affect financial performance. The net sales for the nine months ended September 30, 2024, experienced a $190.9 million unfavorable impact from foreign currency translation.
Operational Risks
Operational risks have been highlighted in the recent earnings reports, particularly regarding cash flows and earnings:
- Net cash provided by operating activities decreased by $511.3 million to $1.82 billion for the nine months ended September 30, 2024, compared to $2.33 billion for the same period in 2023.
- The company reported a net loss of $117.7 million for the nine months ended September 30, 2024, contrasting with net earnings of $820.3 million in the prior year.
Financial Risks
Financial risks include exposure to interest rates and debt obligations:
- The interest expense for the nine months ended September 30, 2024, totaled $429.8 million, a slight decrease from $432.2 million in the same period of 2023.
- Total liabilities as of September 30, 2024, were $24.96 billion, with long-term debt accounting for $14.30 billion.
Strategic Risks
Strategic risks are associated with the company's long-term planning and market positioning:
- The company recorded a net loss on divestitures of approximately $295.8 million for the nine months ended September 30, 2024.
- As of September 30, 2024, the total equity was reported at $19.79 billion, down from $20.47 billion at the end of 2023.
Mitigation Strategies
Mitigation strategies include:
- Continuous monitoring of regulatory changes and maintaining compliance to minimize operational disruptions.
- Strategic divestitures aimed at focusing on core business areas, despite initial losses from divestitures.
- Enhancing product offerings to mitigate competitive pressures, as evidenced by new product sales contributing approximately $497.2 million for the nine months ended September 30, 2024.
| Risk Factor | Impact | Financial Data |
|---|---|---|
| Industry Competition | Net sales decrease | Decrease of $445.4 million or 4% |
| Regulatory Changes | Goodwill impairment charge | $321 million |
| Market Conditions | Foreign currency impact | $190.9 million unfavorable impact |
| Operational Risks | Cash flow decrease | Decrease of $511.3 million |
| Financial Risks | Interest expense | $429.8 million |
| Strategic Risks | Loss on divestitures | $295.8 million |
Future Growth Prospects for Viatris Inc. (VTRS)
Future Growth Prospects for Viatris Inc.
Key Growth Drivers
- Product Innovations: The company has launched new products in 2024 contributing approximately $497.2 million in sales.
- Market Expansions: Net sales in Developed Markets totaled approximately $6.78 billion for the nine months ended September 30, 2024.
- Acquisitions: The cash paid for acquisitions, net of cash acquired, was $350 million related to the Idorsia Transaction.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, total revenues were $11.21 billion, down from $11.59 billion in the prior year, representing a 3% decrease. However, on a constant currency basis, net sales from the remaining business increased by approximately $251.2 million, or 2%, compared to the prior year.
| Segment | Net Sales (2024) | Net Sales (2023) | Change (%) |
|---|---|---|---|
| Developed Markets | $6.78 billion | $7.40 billion | (8.9%) |
| Greater China | $1.64 billion | $1.65 billion | (0.6%) |
| JANZ | $1.01 billion | $1.05 billion | (3.8%) |
| Emerging Markets | $1.74 billion | $1.93 billion | (10.2%) |
Strategic Initiatives or Partnerships
In 2024, the company engaged in strategic partnerships aimed at enhancing its product offerings and market reach. The focus has been on leveraging its existing portfolio while exploring new market segments, particularly in emerging markets.
Competitive Advantages
- Global Reach: The company operates in multiple regions, with net sales from Developed Markets amounting to approximately $6.78 billion for the nine months ended September 30, 2024.
- Diverse Product Portfolio: The top ten products accounted for about 33% of total net sales for the nine months ended September 30, 2024.
- Cost Management: Operating expenses were managed effectively, with total operating expenses for the nine months ended September 30, 2024, at $4.22 billion.
Viatris Inc. (VTRS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Viatris Inc. (VTRS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Viatris Inc. (VTRS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Viatris Inc. (VTRS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.